Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse.

Swedberg MD.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:295-305. doi: 10.1016/j.vascn.2016.05.011. Epub 2016 May 25. Review.

PMID:
27235786
2.

Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839.

Sparve E, Quartino AL, Lüttgen M, Tunblad K, Gårdlund AT, Fälting J, Alexander R, Kågström J, Sjödin L, Bulgak A, Al-Saffar A, Bridgland-Taylor M, Pollard C, Swedberg MD, Vik T, Paulsson B.

J Pharmacol Exp Ther. 2014 Aug;350(2):469-78. doi: 10.1124/jpet.114.215202. Epub 2014 Jun 10.

PMID:
24917547
3.

AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects.

Swedberg MD, Raboisson P.

J Pharmacol Exp Ther. 2014 Aug;350(2):212-22. doi: 10.1124/jpet.114.215137. Epub 2014 May 29.

PMID:
24876235
4.

Effects of the δ opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse.

Hudzik TJ, Pietras MR, Caccese R, Bui KH, Yocca F, Paronis CA, Swedberg MD.

Pharmacol Biochem Behav. 2014 Sep;124:48-57. doi: 10.1016/j.pbb.2014.05.009. Epub 2014 May 22.

PMID:
24857840
5.

mGluR5 antagonist-induced psychoactive properties: MTEP drug discrimination, a pharmacologically selective non-NMDA effect with apparent lack of reinforcing properties.

Swedberg MD, Ellgren M, Raboisson P.

J Pharmacol Exp Ther. 2014 Apr;349(1):155-64. doi: 10.1124/jpet.113.211185. Epub 2014 Jan 28.

PMID:
24472725
6.

A proactive nonclinical drug abuse and dependence liability assessment strategy: a sponsor perspective.

Swedberg MD.

Behav Pharmacol. 2013 Sep;24(5-6):396-402. doi: 10.1097/FBP.0b013e328363d1e2. Review.

PMID:
23907375
7.

Establishment of auditory discrimination and detection of tinnitus induced by salicylic acid and intense tone exposure in the rat.

Sederholm F, Swedberg MD.

Brain Res. 2013 May 13;1510:48-62. doi: 10.1016/j.brainres.2013.03.013. Epub 2013 Mar 25.

PMID:
23535449
8.

Preclinical pharmacology of AZD2327: a highly selective agonist of the δ-opioid receptor.

Hudzik TJ, Maciag C, Smith MA, Caccese R, Pietras MR, Bui KH, Coupal M, Adam L, Payza K, Griffin A, Smagin G, Song D, Swedberg MD, Brown W.

J Pharmacol Exp Ther. 2011 Jul;338(1):195-204. doi: 10.1124/jpet.111.179432. Epub 2011 Mar 28.

PMID:
21444630
9.

A behavioural operant discrimination model for assessment and pharmacological manipulation of visual function in rats.

Carlsson MA, Swedberg MD.

Brain Res. 2010 Mar 19;1321:78-87. doi: 10.1016/j.brainres.2010.01.029. Epub 2010 Jan 25.

PMID:
20097183
10.

Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans.

Marsch LA, Bickel WK, Badger GJ, Rathmell JP, Swedberg MD, Jonzon B, Norsten-Höög C.

J Pharmacol Exp Ther. 2001 Dec;299(3):1056-65.

PMID:
11714895
11.

Synthesis of novel GABA uptake inhibitors. Part 6: preparation and evaluation of N-Omega asymmetrically substituted nipecotic acid derivatives.

Andersen KE, Lau J, Lundt BF, Petersen H, Huusfeldt PO, Suzdak PD, Swedberg MD.

Bioorg Med Chem. 2001 Nov;9(11):2773-85.

PMID:
11597457
12.

Synthesis of novel gamma-aminobutyric acid (GABA) uptake inhibitors. 5.(1) Preparation and structure-activity studies of tricyclic analogues of known GABA uptake inhibitors.

Andersen KE, Sørensen JL, Lau J, Lundt BF, Petersen H, Huusfeldt PO, Suzdak PD, Swedberg MD.

J Med Chem. 2001 Jun 21;44(13):2152-63.

PMID:
11405652
13.

The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance.

Rasmussen T, Fink-Jensen A, Sauerberg P, Swedberg MD, Thomsen C, Sheardown MJ, Jeppesen L, Calligaro DO, DeLapp NW, Whitesitt C, Ward JS, Shannon HE, Bymaster FP.

Schizophr Res. 2001 Apr 15;49(1-2):193-201.

PMID:
11343877
14.

Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive mice.

Rasmussen T, Sauerberg P, Nielsen EB, Swedberg MD, Thomsen C, Sheardown MJ, Jeppesen L, Calligaro DO, DeLapp NW, Whitesitt C, Ward JS, Shannon HE, Bymaster FP, Fink-Jensen A.

Eur J Pharmacol. 2000 Aug 25;402(3):241-6.

PMID:
10958890
15.

Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, Jeppesen L, Sheardown MJ, Sauerberg P, Fink-Jensen A.

Schizophr Res. 2000 May 5;42(3):249-59.

PMID:
10785583
16.

Synthesis of novel GABA uptake inhibitors. 4. Bioisosteric transformation and successive optimization of known GABA uptake inhibitors leading to a series of potent anticonvulsant drug candidates.

Andersen KE, Sørensen JL, Huusfeldt PO, Knutsen LJ, Lau J, Lundt BF, Petersen H, Suzdak PD, Swedberg MD.

J Med Chem. 1999 Oct 21;42(21):4281-91.

PMID:
10543872
17.

Synthesis of novel GABA uptake inhibitors. 3. Diaryloxime and diarylvinyl ether derivatives of nipecotic acid and guvacine as anticonvulsant agents.

Knutsen LJ, Andersen KE, Lau J, Lundt BF, Henry RF, Morton HE, Naerum L, Petersen H, Stephensen H, Suzdak PD, Swedberg MD, Thomsen C, Sørensen PO.

J Med Chem. 1999 Sep 9;42(18):3447-62.

PMID:
10479278
18.

Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.

Shannon HE, Hart JC, Bymaster FP, Calligaro DO, DeLapp NW, Mitch CH, Ward JS, Fink-Jensen A, Sauerberg P, Jeppesen L, Sheardown MJ, Swedberg MD.

J Pharmacol Exp Ther. 1999 Aug;290(2):901-7.

PMID:
10411607
19.

3-(5-Alkylamino-4-isoxazolyl)-1,2,5,6-tetrahydropyridines: a novel class of central nicotinic receptor ligands.

Olesen PH, Swedberg MD, Rimvall K.

Bioorg Med Chem. 1998 Sep;6(9):1623-9.

PMID:
9801833
20.

Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity.

Sauerberg P, Jeppesen L, Olesen PH, Rasmussen T, Swedberg MD, Sheardown MJ, Fink-Jensen A, Thomsen C, Thøgersen H, Rimvall K, Ward JS, Calligaro DO, DeLapp NW, Bymaster FP, Shannon HE.

J Med Chem. 1998 Oct 22;41(22):4378-84.

PMID:
9784113
21.

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane .

Bymaster FP, Shannon HE, Rasmussen K, Delapp NW, Mitch CH, Ward JS, Calligaro DO, Ludvigsen TS, Sheardown MJ, Olesen PH, Swedberg MD, Sauerberg P, Fink-Jensen A.

Eur J Pharmacol. 1998 Sep 4;356(2-3):109-19.

PMID:
9774240
22.

Reinforcing effects of nicotinic compounds: intravenous self-administration in drug-naive mice.

Rasmussen T, Swedberg MD.

Pharmacol Biochem Behav. 1998 Jun;60(2):567-73.

PMID:
9632242
23.
24.

1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists.

Ward JS, Merritt L, Calligaro DO, Bymaster FP, Shannon HE, Mitch CH, Whitesitt C, Brunsting D, Sheardown MJ, Olesen PH, Swedberg MD, Jeppesen L, Sauerberg P.

J Med Chem. 1998 Jan 29;41(3):379-92.

PMID:
9464368
25.

Conformationally constrained analogues of the muscarinic agonist 3-(4-(methylthio)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyr idine. Synthesis, receptor affinity, and antinociceptive activity.

Sauerberg P, Olesen PH, Sheardown MJ, Rimvall K, Thøgersen H, Shannon HE, Sawyer BD, Ward JS, Bymaster FP, DeLapp NW, Calligaro DO, Swedberg MD.

J Med Chem. 1998 Jan 1;41(1):109-16.

PMID:
9438027
26.

Pharmacology of butylthio[2.2.2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity.

Shannon HE, Sheardown MJ, Bymaster FP, Calligaro DO, Delapp NW, Gidda J, Mitch CH, Sawyer BD, Stengel PW, Ward JS, Wong DT, Olesen PH, Suzdak PD, Sauerberg P, Swedberg MD.

J Pharmacol Exp Ther. 1997 May;281(2):884-94.

PMID:
9152398
27.

Butylthio[2.2.2] (NNC 11-1053/LY297802): an orally active muscarinic agonist analgesic.

Swedberg MD, Sheardown MJ, Sauerberg P, Olesen PH, Suzdak PD, Hansen KT, Bymaster FP, Ward JS, Mitch CH, Calligaro DO, Delapp NW, Shannon HE.

J Pharmacol Exp Ther. 1997 May;281(2):876-83.

PMID:
9152397
28.

M1 receptor agonist activity is not a requirement for muscarinic antinociception.

Sheardown MJ, Shannon HE, Swedberg MD, Suzdak PD, Bymaster FP, Olesen PH, Mitch CH, Ward JS, Sauerberg P.

J Pharmacol Exp Ther. 1997 May;281(2):868-75.

PMID:
9152396
29.

Muscarinic analgesics with potent and selective effects on the gastrointestinal tract: potential application for the treatment of irritable bowel syndrome.

Mitch CH, Brown TJ, Bymaster FP, Calligaro DO, Dieckman D, Merrit L, Peters SC, Quimby SJ, Shannon HE, Shipley LA, Ward JS, Hansen K, Olesen PH, Sauerberg P, Sheardown MJ, Swedberg MD, Suzdak P, Greenwood B.

J Med Chem. 1997 Feb 14;40(4):538-46.

PMID:
9046345
30.

In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist.

Shannon HE, Womer DE, Bymaster FP, Calligaro DO, DeLapp NC, Mitch CH, Ward JS, Whitesitt CA, Swedberg MD, Sheardown MJ, Fink-Jensen A, Olesen PH, Rimvall K, Sauerberg P.

Life Sci. 1997;60(13-14):969-76. Review.

PMID:
9121363
31.

NNC-19-1228 and NNC 22-0031, novel neuroleptics with a "mesolimbic-selective" behavioral profile.

Nielsen EB, Hansen JB, Grłnvald FC, Swedberg MD, Scheideler M.

Psychopharmacology (Berl). 1997 Jan;129(2):168-78.

PMID:
9040123
32.

Anticonvulsant profile of the imidazoquinazolines NNC 14-0185 and NNC 14-0189 in rats and mice.

Jackson HC, Hansen HC, Kristiansen M, Suzdak PD, Klitgaard H, Judge ME, Swedberg MD.

Eur J Pharmacol. 1996 Jul 11;308(1):21-30.

PMID:
8836628
33.

Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.

Ward JS, Merritt L, Calligaro DO, Bymaster FP, Shannon HE, Sawyer BD, Mitch CH, Deeter JB, Peters SC, Sheardown MJ, Olesen PH, Swedberg MD, Sauerberg P.

J Med Chem. 1995 Sep 1;38(18):3469-81.

PMID:
7658434
34.
35.

Muscarinic agonists as analgesics. Antinociceptive activity versus M1 activity: SAR of alkylthio-TZTP's and related 1,2,5-thiadiazole analogs.

Sauerberg P, Olesen PH, Sheardown MJ, Suzdak PD, Shannon HE, Bymaster FP, Calligaro DO, Mitch CH, Ward JS, Swedberg MD.

Life Sci. 1995;56(11-12):807-14.

PMID:
10188779
37.

Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232).

Bymaster FP, Wong DT, Mitch CH, Ward JS, Calligaro DO, Schoepp DD, Shannon HE, Sheardown MJ, Olesen PH, Suzdak PD, Swedberg MD, Sauerberg P.

J Pharmacol Exp Ther. 1994 Apr;269(1):282-9.

PMID:
7909558
38.

Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.

Shannon HE, Bymaster FP, Calligaro DO, Greenwood B, Mitch CH, Sawyer BD, Ward JS, Wong DT, Olesen PH, Sheardown MJ, Swedberg MD, Suzdak PD, Sauerberg P.

J Pharmacol Exp Ther. 1994 Apr;269(1):271-81.

PMID:
7909557
39.

D-16949 (anpirtoline): a novel serotonergic (5-HT1B) psychotherapeutic agent assessed by its discriminative effects in the rat.

Swedberg MD, Shannon HE, Nickel B, Goldberg SR.

J Pharmacol Exp Ther. 1992 Dec;263(3):1015-22.

PMID:
1335050
40.

The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats.

Fink-Jensen A, Suzdak PD, Swedberg MD, Judge ME, Hansen L, Nielsen PG.

Eur J Pharmacol. 1992 Sep 22;220(2-3):197-201.

PMID:
1425991
41.

In vivo labeling of the central GABA uptake carrier with 3H-Tiagabine.

Suzdak PD, Swedberg MD, Andersen KE, Knutsen LJ, Braestrup C.

Life Sci. 1992;51(24):1857-68.

PMID:
1333027
42.

Discriminative stimulus effects of intravenous l-nicotine and nicotine analogs or metabolites in squirrel monkeys.

Takada K, Swedberg MD, Goldberg SR, Katz JL.

Psychopharmacology (Berl). 1989;99(2):208-12.

PMID:
2508155
43.
44.

Role of central noradrenaline neurons in the contextual control of latent inhibition in taste aversion learning.

Mohammed AK, Callenholm NE, Järbe TU, Swedberg MD, Danysz W, Robbins TW, Archer T.

Behav Brain Res. 1986 Aug;21(2):109-18.

PMID:
3755946
45.
46.

Drug discrimination procedures: roles of relative stimulus control in two-drug cases.

Swedberg MD, Järbe TU.

Psychopharmacology (Berl). 1985;86(4):444-51.

PMID:
3929316
47.

Ethanol as a discriminative stimulus: effects of cyanamide, acetaldehyde and chlormethiazole.

Järbe TU, Hiltunen AJ, Swedberg MD.

Med Biol. 1982 Dec;60(6):298-306.

PMID:
7162223
48.

Discriminative stimulus properties of drugs: a brief history and a selective review.

Järbe TU, Swedberg MD.

Scand J Psychol. 1982;Suppl 1:72-8. No abstract available.

PMID:
7187991
49.
50.

Evidence supporting lack of discriminative stimulus properties of a combination of naltrexone and morphine.

Järbe TU, Loman P, Swedberg MD.

Pharmacol Biochem Behav. 1979 Apr;10(4):493-7.

PMID:
461479

Supplemental Content

Loading ...
Support Center